ArticleFrontiers in pharmacology2025

Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial.

Cuiyun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.